Ketotifen Fumarate
Phase 3Small molecule
Tanabe Pharma CorporationKetotifen Fumarate is one of 39 small molecule programs targeting Contracture. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Ciclosporin
NovartisPhase 3
Tagamet
DDT MedTech, LLC
Phase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
VC005
JJiangsu vcare pharmaceutical technology co., LTD
Phase 3
Elidel
BayerPhase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
Adquey
AAcrotech Biopharma Inc.
Phase 3
Benvitimod
PPeking University People's Hospital
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Atopic Dermatitis1 trial
Chronic1 trial
Chronic Widespread Pain and White Blood Cell Activation
Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 3·NCT02984397·44 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ketotifen Fumarate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company